Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Number of trips to Whoosh has increased by 92%

10/3/23 WUSH

Rosseti asks to prohibit consumers from switching to their own generation free of charge

10/3/23 FEES

Fesco increased its container fleet to 170 thousand TEU

10/3/23 FESH

Sollers will receive a preferential loan for localization of gearboxes

10/3/23 SVAV

Ghana approves Pecan field development plan with participation of Lukoil

10/3/23 LKOH

Moscow Exchange is thinking about the DFA for art objects

10/3/23 MOEX

Etalon split the depository program

10/3/23 ETLN

Ministry of Finance expects Sberbank to update its dividend record

10/3/23 SBER

Rosneft increased oil production potential in the Irkutsk region

10/2/23 ROSN

Tesla sales up 26.5% in Q3

10/2/23 TSLA